Crispr Therapeutics AG is trading 6.1% up at $52.84 as the stock rebounds from recent biotech sector weakness amid a broader market rally and positive pipeline sentiment.
- The advance follows a shift in risk appetite that has lifted major U.S. indices by more than 1% as geopolitical tensions ease.
- Investor confidence is further bolstered by earlier June analyst price target hikes and optimism regarding the company's gene-editing pipeline.
- The stock is currently testing near-term resistance levels after recovering from last week's downward pressure.